Alexza partners with Teva for US Adasuve launch
This article was originally published in Scrip
Executive Summary
Alexza Pharmaceuticals will receive $40 million up front under a license and supply agreement with Teva Pharmaceuticals USA to commercialize Adasuve (loxapine) inhalation powder.